Company: CMND
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112329
Chunk: 23

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 23
---
 5,509,768 Common Shares and/or pre-funded warrants in the Second November 2025 Offering at a public       
 offering price of $0.25 per Common Share and $0.2499 per pre-funded warrant for net proceeds of approximately $1.3 million, after deducting     
 offering expenses payable by us and (iv) the issuance of 2,090,987 Common Shares for aggregate gross proceeds of approximately $187,000         
 as a result of the exercise of warrants to purchase 2,894,769 Common Shares for cash and on a cashless basis issued in our financings           
 in April 2023 and January 2024, as if such events had occurred on July 31, 2025 (collectively, the “Pro Forma Adjustments”);                    
 and                                                                                                                                             |

| ● | on a pro forma as adjusted basis,                                                                                                    
 to give further effect to the issuance and sale of 10,925,000 Common Shares in this offering at a public offering price of $0.20 per 
 Common Share, after deducting offering expenses payable by us, as if the sale had occurred on July 31, 2025.                         |

You should read this information
in conjunction with our consolidated financial statements and the related notes appearing at the end of this prospectus and the “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” section and other financial information contained in this
prospectus.

|                                      |     | As of  July 31, 2025 |         |   |     |       |         |   |     |          |         |   |
|:-------------------------------------|:----|:---------------------|--------:|:--|:----|:------|--------:|:--|:----|:---------|--------:|:--|
| U.S. dollars in thousands            |     | Actual               |         |   |     | Pro   
 Forma |         |   |     | Pro      
 Forma As 
 Adjusted |         |   |
| Cash and cash equivalents            |     | $                    |   3,495 |   |     | $     |   7,993 |   |     | $        |  10,128 |   |
| Derivative warrants liability        |     |                      |  (2,179 | ) |     |       |  (1,782 | ) |     |          |  (1,782 | ) |
| Shareholders’ equity